Press release

Agilent Announces Unique Portfolio to Advance Immunotherapy

businesswire,
0
Sponsored by Businesswire

Agilent
Technologies Inc. (NYSE: A) announces a unified portfolio of
products for immunotherapy researchers. The innovative solution will
showcase at Immunology
2019, the 103rd Annual Meeting of the
American Association of Immunologists (AAI), taking place in San
Diego, CA on May 9-13, 2019.

“Immunotherapy is changing the landscape of cancer treatment, but most
of the available tools are adapted and not purpose-built for this
cell-centric workflow,” said David Ferrick, Ph.D., senior director of
the Cell Analysis Division at Agilent Technologies. “This is why we have
placed so much emphasis on assembling and harmonizing innovative
cell-based solutions. We want to enable researchers and developers to
overcome the challenges and capture the opportunities of this rapidly
growing field.”

“To find the answers, flow cytometry approaches, kinetic measures of
live-cell metabolism, and quantifying the ability of T cells to kill
targets over time, are all aspects that can be investigated now with the
tools that Agilent provides,” said Carl June, MD, professor in
immunotherapy at the Perelman School of Medicine at the University of
Pennsylvania and Abramson Cancer Center. “Any cell-based assay that
improves the probability that you’re going to have an effective cell
product will be something that everyone wants.”

Agilent’s new offering includes four purpose-built components that
naturally complement:

  • Agilent
    SureGuide Chemically Synthesized sgRNAs:     Deliver the best guides
    to enable the full potential of CRISPR for cellular engineering and
    immunotherapy.
  • NovoCyte
    Quanteon Flow Cytometer:     Quickly and accurately immunophenotype
    with up to 25 channels of fluorescence using the most sensitive
    silicon photomultiplier detector technology on the market. Experience
    the new standard in flow cytometry.
  • xCELLigence
    RTCA eSight:     Capture dynamic cell behavior and follow the biology
    that can be missed by labor-intensive endpoint assays to quantify, in
    real-time critical events like cancer cell killing.
  • Agilent
    Seahorse XF Analyzers:     Discover and tune immune cell metabolism to
    mount a sustained and robust anti-tumor response. XF analyzers are the
    market leading choice for this type of work.

An Agilent workshop titled Breakthroughs in immunotherapy: Tune the
drivers of immune cell potency, fate and persistence, presented by
David Ferrick, will be held on Sunday, May 12, 10:00 – 10:45 a.m. in
Room 2 of the San Diego Convention Center, Exhibit Halls F & G. To learn
more, visit the Agilent booth #1315 and the ACEA (a part of Agilent)
booth #1030 at Immunology 2019, or go to www.agilent.com/en/solutions/cell-metabolism/immune-cell-therapy.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences,
diagnostics and applied chemical markets. With more than 50 years of
insight and innovation, Agilent instruments, software, services,
solutions, and people provide trusted answers to customers’ most
challenging questions. The company generated revenues of $4.91 billion
in fiscal 2018 and employs 15,300 people worldwide. Information about
Agilent is available at www.agilent.com.
To receive the latest Agilent news, subscribe to our Newsroom.
Follow Agilent on LinkedIn,
Twitter,
and Facebook.